News and Press Releases
Valo Therapeutics receives $4.6 million non-dilutive funding from Tekes, in order to accelerate development of a novel oncolytic virus-based cancer immunotherapy
Helsinki, Finland, July 4, 2017. The Finnish Funding Agency for Innovation, Tekes, has granted Valo Therapeutics a $4.6 million non-dilutive loan for the preparation of a Phase I trial of a novel oncolytic virus-based cancer immunotherapy called PeptiCRAd. Valo Therapeutics has now raised $8 million (including $3.4m seed capital in January 2017) towards its mission to provide cancer patients with less toxic and longer lasting therapeutic options. Valo Therapeutics aims at combining the PeptiCRAd technology with check point inhibitors in
Valo Therapeutics recruits Antti Vuolanto as COO
Antti Vuolanto has recently joined Valo Therapeutics to fulfill the position of COO, bringing over 10 years of biotechnology and operational management experience to the company.
Adenoviruses and the immune system join forces against cancer
IDIBELL researchers have developed an oncolytic virus capable of redirecting the patient's immune system against their tumor cells
Immuno-oncology News: Valo Therapeutics Developing Unique Viral-particle Cancer Vaccine
A new cancer vaccine that uses viral particles to trigger strong immune responses against cancer cells is being developed by Valo Therapeutics.
Drug Discovery and Development- "Immunotherapy: Training The Body to Fight Cancer"
Top researchers in the field of immuno-oncology show promising results using peptide / antibody vaccine combination treatments in terminally ill patients with metastatic tumours
Valo Therapeutics closes seed fundraising round to develop a novel oncolytic virus-based cancer immunotherapy
A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.
Valo Therapeutics päätti siemenrahoituskierroksen kehittääkseen uutta onkolyyttiseen virukseen perustuvaa syövän immunoterapiaa
Valo Therapeutics, spin-out -yhtiö Helsingin yliopistosta, kehittää uutta onkolyyttiseen virukseen perustuvaa syövän immunoterapiaa, jolla voidaan hoitaa useita eri syöpätyyppejä.
Oncolytic Viruses "undervalued" technology with strong growth perspectives
Major acquisitions (>$1bn) have been a game changer for the field of oncolytic viruses, now recognized as a promising new therapeutic approach for cancer treatment.
Valo Therapeutics recruits Petri Priha as Vice President CMC
Petri Priha has recently joined Valo Therapeutics to fulfill the position of Vice President of CMC, bringing over 20 years of Biopharmaceutical industry and product development experience to the company.
Start-Up Oncolytic Virus firm Trieza licenses Abzena antibody
Trieza Therapeutics negotiates an exclusive worldwide license to an antibody sequence generated by Abzena
Viral therapy leaders announce formation of new immunotherapy company
Pioneers in the oncolytic virus and gene therapy fields announce the formation of IGNITE Immunotherapy Inc., a new company focused on oncolytic cancer vaccine discovery and development. The lead investor, Pfizer Inc., will collaborate on IGNITE’s new research program to help discover potential novel vaccinia viruses.